Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaella Origa

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Cancer|November 2, 2022
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021Raffaella Origa, Barbara Gianesin, Filomena Longo, et al.
The Lancet. Haematology|February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
The Lancet. Haematology|May 30, 2020
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trialAurelio Maggio, Antonis Kattamis, Mariagrazia Felisi, et al.
Haematologica|September 20, 2015
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disordersLouise de Swart, Jan C M Hendriks, Lisa N van der Vorm, et al.
Haematologica|January 7, 2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohortMaddalena Casale, Gian Luca Forni, Elena Cassinerio, et al.
Haematologica|January 23, 2025
Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide studyBarbara Gianesin, Frédéric B Piel, Khaled M Musallam, et al.
American Journal of Hematology|December 19, 2025
A Combination of Plerixafor and Filgrasting Promotes Successful CD34+ Cell Collection for CRISPR/Cas9 Therapy in Sickle Cell Disease Patients With Insufficient Response to Plerixafor AloneFrancesco Arcioni, Marta Bonetti, Antonella Sau, et al.
British Journal of Haematology|March 18, 2026
Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patientsBarbara Gianesin, Antonietta Zappu, Giovanni Battista Ferrero, et al.
Nature Medicine|January 22, 2019
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemiaSarah Marktel, Samantha Scaramuzza, Maria Pia Cicalese, et al.
Haematologica|August 18, 2025
Pregnancy and childbirth in women with thalassemia: past and presentAnna Demurtas, Barbara Gianesin, Antonietta Zappu, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Cancer|November 2, 2022
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021Raffaella Origa, Barbara Gianesin, Filomena Longo, et al.
The Lancet. Haematology|February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
The Lancet. Haematology|May 30, 2020
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trialAurelio Maggio, Antonis Kattamis, Mariagrazia Felisi, et al.
Haematologica|September 20, 2015
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disordersLouise de Swart, Jan C M Hendriks, Lisa N van der Vorm, et al.
Haematologica|January 7, 2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohortMaddalena Casale, Gian Luca Forni, Elena Cassinerio, et al.
Haematologica|January 23, 2025
Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide studyBarbara Gianesin, Frédéric B Piel, Khaled M Musallam, et al.
American Journal of Hematology|December 19, 2025
A Combination of Plerixafor and Filgrasting Promotes Successful CD34+ Cell Collection for CRISPR/Cas9 Therapy in Sickle Cell Disease Patients With Insufficient Response to Plerixafor AloneFrancesco Arcioni, Marta Bonetti, Antonella Sau, et al.
British Journal of Haematology|March 18, 2026
Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patientsBarbara Gianesin, Antonietta Zappu, Giovanni Battista Ferrero, et al.
Nature Medicine|January 22, 2019
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemiaSarah Marktel, Samantha Scaramuzza, Maria Pia Cicalese, et al.
Haematologica|August 18, 2025
Pregnancy and childbirth in women with thalassemia: past and presentAnna Demurtas, Barbara Gianesin, Antonietta Zappu, et al.
Pageof 10